Skip to main content

Table 1 Clinicopathologic characteristics by IHC subtype for women with invasive breast cancer, Norway 2005–2015 age 20–74 years

From: In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study

IHC subtype ER+PR+HER2− ER+PR−HER2− ER+PR+HER2+ ER+PR−HER2+ ER−PR−HER2+ (HER2pos) ER−PR−HER2− (TNBC) Missinga Total
N % N % N % N % N % N % N % N %
Total 13,010 100 3036 100 1424 100 834 100 1103 100 2114 100 2616 100 24,137 100.0
Age
 20–39 545 4.2 132 4.3 180 12.6 69 8.3 121 11.0 288 13.6 159 6.1 1494 6.2
 40–49 2799 21.5 371 12.2 445 31.3 163 19.5 247 22.4 467 22.1 480 18.3 4972 20.6
 50–59 4112 31.6 1015 33.4 361 25.4 305 36.6 371 33.6 639 30.2 883 33.8 7686 31.8
 60–69 4489 34.5 1212 39.9 360 25.3 243 29.1 286 25.9 557 26.3 884 33.8 8031 33.3
 70–74 1065 8.2 306 10.1 78 5.5 54 6.5 78 7.1 163 7.7 210 8.0 1954 8.1
Year
 2005–2008 3865 29.7 987 32.5 416 29.2 224 26.9 365 33.1 736 34.8 1508 57.6 8101 33.6
 2009–2012 4708 36.2 1035 34.1 578 40.6 316 37.9 402 36.4 728 34.4 890 34.0 8657 35.9
 2013–2015 4437 34.1 1014 33.4 430 30.2 294 35.3 336 30.5 650 30.7 218 8.3 7379 30.6
Grade
 I: low 3608 29.3 614 21.7 79 5.9 36 4.8 15 1.5 30 1.5 494 23.2 4876 21.9
 II: intermediate 6849 55.6 1459 51.6 666 50.2 331 43.8 244 24.9 340 17.5 968 45.4 10,857 48.7
 III: high 1860 15.1 752 26.6 583 43.9 388 51.4 719 73.5 1571 80.9 671 31.5 6544 29.4
 Missing 693   211   96   79   125   173   483   1860  
Ki67b
 0–14.9% 2173 37.2 388 30.5 75 14.3 22 6.4 15 4.3 37 4.7 94 30.8 2804 29.7
 15.0–30.0% 2138 36.6 384 30.2 128 24.3 106 30.9 68 19.7 64 8.1 93 30.5 2981 31.6
 30.1–100% 1531 26.2 501 39.4 323 61.4 215 62.7 263 76.0 692 87.3 118 38.7 3643 38.6
 Missing 2011–2015 1110   293   207   142   186   246   299   2483  
 Missing 2005–2010                12,226  
Tumour size
 pT1, 0–20 mm 8407 72.2 1735 66.9 718 62.3 372 58.5 434 53.5 929 54.6 1415 69.9 14,010 68.2
 pT2, 21–50 mm 2932 25.2 778 30.0 400 34.7 242 38.1 329 40.6 725 42.6 538 26.6 5944 28.9
 pT3, > 50 mm 186 1.6 55 2.1 19 1.6 12 1.9 22 2.7 23 1.4 29 1.4 346 1.7
 pT4: spread, any size 115 1.0 24 0.9 16 1.4 10 1.6 26 3.2 23 1.4 43 2.1 257 1.3
 Missing 1370   444   271   198   292   414   591   3580  
Nodal status
 pN0, 0 nodes+ 8141 67.4 1816 65.2 716 55.3 376 50.9 441 45.3 1196 63.1 1503 64.3 14,189 64.2
 pN1, 1–3 nodes+ 3333 27.6 819 29.4 479 37.0 282 38.2 424 43.5 599 31.6 745 31.9 6681 30.2
 pN2, 4–9 nodes+ 413 3.4 90 3.2 73 5.6 55 7.4 67 6.9 62 3.3 60 2.6 820 3.7
 pN3, 10+ nodes+ 187 1.5 60 2.2 27 2.1 26 3.5 42 4.3 39 2.1 28 1.2 409 1.9
 Missing 936   251   129   95   129   218   280   2038  
TNM stage
 I 6619 53.0 1406 48.5 519 38.2 266 33.8 296 28.4 730 36.8 1236 50.0 11,072 48.1
 II 4519 36.2 1117 38.6 589 43.3 324 41.2 465 44.6 953 48.1 887 35.9 8854 38.5
 III 1056 8.5 285 9.8 185 13.6 144 18.3 225 21.6 234 11.8 225 9.1 2354 10.2
 IV 287 2.3 88 3.0 66 4.9 53 6.7 56 5.4 65 3.3 123 5.0 738 3.2
 Missing 529   140   65   47   61   132   145   1119  
  1. aMissing on any of ER/PR/HER2 (n = 2351), ER−PR+HER2− (n = 176), or ER−PR+HER2+ (n = 89)
  2. bKi67 only available years 2011–2015
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us